How fashions fade. A decade ago, “pure pharma” companies such as Roche and AstraZeneca were a shrinking minority. Novartis exemplified a trend for diversification. Now, the Swiss giant is shedding non-core businesses.
Selling its generic drugs business Sandoz — a possibility mooted by boss Vas Narasimhan on Tuesday — would be the final step in creating a drugs giant narrowly focused on innovative medicines.
Novartis plans to complete its strategic review of Sandoz by the end of next year, exploring all options including hanging on to the unit. Third-quarter results showed why it might want to spin off or sell the generics business.
您已閱讀29%（640字），剩餘71%（1554字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。